MedTrace Logo

Study Evaluating Efficacy and Safety of PF-04523655 Versus Laser in Subjects With Diabetic Macular Edema

NCT00701181 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 184

Last updated 2012-10-11

No results posted yet for this study

Summary

To evaluate the effectiveness of study drug in improving visual acuity compared to laser treatment in the patients with diabetic macular edema

Conditions

Interventions

PROCEDURE

Laser Treatment

Necessity of laser treatment is assessed every three months.

DRUG

PF-04523655 high

3 mg intravitreal injection

DRUG

PF-04523655 middle

1 mg intravitreal injection

DRUG

PF-04523655 low

0.4 mg intravitreal injection

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • Quark Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-06-30
Primary Completion
2011-01-31
Completion
2011-01-31

Countries

  • United States
  • Denmark
  • Germany
  • India
  • Israel
  • Italy
  • Peru
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00701181 on ClinicalTrials.gov